Open AccessThe Consortium for the early identification of Alzheimer's disease–Quebec (CIMA‐Q)
Author(s) -
Belleville Sylvie,
LeBlanc Andréa C.,
Kergoat MarieJeanne,
Calon Frédéric,
Gaudreau Pierrette,
Hébert Sébastien S.,
Hudon Carol,
Leclerc Nicole,
Mechawar Naguib,
Duchesne Simon,
Gauthier Serge,
Bellec Pierre,
Belleville Sylvie,
Bocti Christian,
Calon Frédéric,
Chertkow Howard,
Collins Louis,
Cunnane Stephen,
Duchesne Simon,
Gaudreau Pierrette,
Gauthier Serge,
Hébert Sébastien S.,
MarieJeanneKergoat Carol Hudon,
LeBlanc Andréa C.,
Leclerc Nicole,
Mechawar Naguib,
Philips Natalie,
Soucy JeanPaul,
Dang Vu Thien Thanh,
Verret Louis,
Villalpando Juan Manuel
Publication year - 2019
Publication title -
alzheimer's and dementia: diagnosis, assessment and disease monitoring
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.497
H-Index - 37
ISSN - 2352-8729
DOI - 10.1016/j.dadm.2019.07.003
Subject(s) - dementia , cognitive decline , lumbar puncture , medicine , neuroimaging , disease , neuropsychology , positron emission tomography , magnetic resonance imaging , cognition , peripheral blood mononuclear cell , alzheimer's disease , cerebrospinal fluid , oncology , bioinformatics , pathology , psychiatry , radiology , biology , biochemistry , in vitro
The Consortium for the early identification of Alzheimer's disease–Quebec (CIMA‐Q) created a research infrastructure to recruit, characterize, and track disease progression in individuals at risk of dementia. Methods CIMA‐Q established standardized clinical, neuropsychological, neuroimaging, blood (plasma, serum, RNA, genomic DNA), cryopreserved peripheral blood mononuclear cells, and cerebrospinal fluid collection protocols. These data and biological materials are available to the research community. Results In phase 1, 115 persons with subjective cognitive decline, 88 with mild cognitive impairment, 31 with early probable Alzheimer's disease, and 56 older adults with no worries nor impairments received detailed clinical and cognitive evaluations as well as blood and peripheral blood mononuclear cells collections. Among them, 142 underwent magnetic resonance imaging, 29 a 18 fluorodeoxyglucose positron emission tomography, and 60 a lumbar puncture. Discussion CIMA‐Q provides procedures and resources to identify early biomarkers and novel therapeutic targets, and holds promise for detecting cognitive decline in Alzheimer's disease.